'251-labelled F(ab')2 fragment of the sarcoma specific antibody TP-1. Specific targeting of the human tumour cells was demonstrated in both mice and pigs. The target:blood ratios were comparable in the two species, reaching a maximum of about 15 after 24 h with the Fab preparation, and a ratio of 25 after 72 h with the F(ab')2. The target uptake relative to injected dose was lower in pigs than in mice, but the difference between the two species was smaller than expected, presumably due to a slower antibody clearance in the pigs than in the mice. An artificial cell targeting system like this has several advantages in the search for solutions to many of the fundamental problems experienced in immunotargeting. Firstly, parallel binding experiments can be carried out in vitro with the same target. Because in vitro results are only influenced by the diffusion into the DC and the immunological binding characteristics of the antibodies, targeting differences between antibody preparations due to these factors can then be distinguished from differences due to pharmacokinetical properties. Secondly, the animals can be implanted with any type and number of target Recently, a novel method for preclinical in vivo evaluation of anti-tumour MoAb was published from our institution. The method is based on diffusion chambers implanted in the peritoneal cavity of conventional laboratory animals, and was successfully used for targeting of antigen-coated polymer particles (Fjeld et al., 1988 (Buchegger et al., 1983; Andrew et al., 1988) . Two fragmented MoAb will be tested in the DC model in this paper.
Materials and methods

Animals
Mice The mice were randomly bred females (NMRI/Bom), [8] [9] [10] [11] [12] weeks of age and 20-25 g in weight.
Pigs Female domestic pigs were used. These animals were 4 months of age and 20 kg in weight.
Difusion chambers (DC) Preparation of DC We used the same type of chambers as described in our previous work on DC with antigen-coated polymer particles (Fjeld et al., 1988) . The DC consisted of two micropore membranes (Millipore GSWP, mean pore diameter 0.22 jAm) heat sealed to both sides of a 2 mm thick acrylic plastic ring, outer diameter 13 mm (Benestad & Reikvam, 1975 , and the sarcoma specific MoAb TP-1 binds to OHS epitopes.
Antibodies
The fragmented antibody preparations used The monoclonal antibody H7 (IgG2a) recognises the three common allelic variants of PLALP (Millan & Stigbrand, 1983) . The monoclonal antibody TP-1 (IgG2a) ) is specific for an epitope on a sarcoma associated antigen (Bruland et al., 1988) . The immunoglobulin fractions were separated from ascites with affinity chromatography on protein-A Sepharose columns (Pharmacia, Sweden), and purity was controlled with Fast Protein Liquid Chromatography (FPLC, Pharmacia, Sweden), or polyacrylamide gel electrophoresis, as earlier described for both H7 (Fjeld et al., 1988) , and TP-1 (Bruland et al., 1987) .
The two MoAb were enzymatically digested before they were used in vivo. H7 was enzymatically fragmented to Fab with papain (Goding, 1983; Fjeld et al., 1988) , and TP-1 to F(ab')2 with pepsin (Parham, 1983; Bruland et al., 1987) .
Iodination of antibodies The fragmented antibodies were '251-labelled with Iodogen (Pierce, USA) as oxidant (Fracker & Speck, 1978) . We followed a standard procedure established in our laboratory (Paus et al., 1982) .
Quality control of the iodinated antibodies Binding assays were carried out by mixing 50 ILI of '25I-labelled MoAb dilution with 50 ,sl of serial dilutions of Hep-2 or OHS cells, respectively. The reactants had been diluted in PBS with 0.1 % BSA. The reaction mixtures were incubated at 20°C for at least 3 h with continuous shaking. Free, labelled MoAb were then separated from cell-bond MoAb by washing twice with 1 ml of the dilution buffer. The cells were collected by centrifugation, and the bound radioactivity was counted in a gamma-counter. The immunoreactive fraction (F) of the labelled antibody preparation, the antibody association constant (Ka) and the number of binding sites (S) per cell were calculated from the experimental data on the assumption that the reactions obey the first order law of mass action. A computerised iteration technique was utilised to achieve the parameter values that give optimal fitness of the experimental values with the mass action law (Fjeld & Pigs The pigs remained anaesthetised during the first 2-3 h period after the DC implantation, because multiple blood samples were collected during this period. The blood was collected from the ear vein, or from veins in the thoracic outlet. They were killed by an overdose of phenobarbitone after a period of 1-3 days, depending on which antibody preparation that had been injected. Like in the mouse experiments, the distribution and tumour cell targeting of the labelled antibodies were studied by recording in a gammacounter the radioactivity in blood, various tissues, and all the different DC in the peritoneal cavity.
Results
Binding characteristics of the antibodies and the tumour cells
The two '25I-labelled antibody preparations chosen for the targeting experiments were first tested in vitro against cell suspensions from the cell lines Hep-2 and OHS. The Fab fragment of the MoAb H7 (H7-Fab) did bind to Hep-2, and the F(ab')2 fragment of TP-1 (TP-1-F(ab')2) to OHS ( Figure  1 ). The non-specific binding of H7-Fab to OHS and of TP-l-F(ab')2 to Hep-2 was only about 1% of total radioactivity (not shown in Figure 1 ).
The binding parameters of the iodinated preparations were then estimated, using a mathematical model derived from the first order law of mass action. A computerised non-linear least-squares fit to the experimental data yielded the binding parameters (Fjeld & Skretting, manuscript in preparation) .
The estimated association constant of H7-Fab was closed to ten times the association constant of the TP-1-F(ab')2, whereas the immunoreactive fraction as well as the number of binding sites per target cell was higher for the TP-l-F(ab')2 than for H7-Fab (Table I) .
Immunotargeting of tumour cells in immunocompetent mice The two antibody preparations had previously been used in the nude mouse xenograft model system (Bruland et al., 1987; Fjeld, unpublished results). Moreover, the H7 preparation had also shown specific targeting of antigen coated polymer particles in normal mice (Fjeld et al., 1988) . The in vivo uptake of a radiolabelled antibody in its specific target depends, among several other factors, on the antibody concentration in the blood. Thus, the DC targeting experiments were preceded by blood clearance studies with the anti-tumour antibodies in immunocompetent mice (Figure 2) . The Fab fragment of H7 was, as expected, more rapidly cleared from the blood circulation than the larger F(ab')2 fragment of TP-1. The next day after the injection the blood level of both antibodies was low, but significantly different, with a value of 0.1% injected dose for H7-Fab and 5% for TP-I-F(ab')2. It was necessary to wait for 2 more days before the level of the TP-1 preparation had decreased to the low level reached by the H7 preparation after only 1 day.
Based on these blood clearance studies, it was decided to compare the biodistribution and tumour cell targeting 24 and 72 h after the antibody injection. Each mouse carried two DC, one filled with 2 x 105 OHS cells, and the second with the same amount of Hep-2 cells. The results demonstrated that the anti-sarcoma antibody TP-I-F(ab')2 was specifically bound to DC filled with cells from the sarcoma cell line OHS, whereas the anti-PLALP antibody H7-Fab was specifically bound to DC containing the PLALP expressing Hep-2 cells (Figure 3) . Moreover, the DC:blood ratio with the TP-1 preparation was significantly increased in the period from 1 to 3 days. In contrast, the DC:blood ratio with the H7 preparation decreased from day 1 to day 3. The explanation to the latter seemed to be that there had been a net release of radioactivity from the target in the period between day 1 and day 3 (Table II) , whereas the blood level remained almost unchanged (Figure 2) . The explanation to the increased target:blood ratio with TP-1-F(ab')2 seemed to be no change, or a minor increase, in the net radioactivity uptake in the DC shown. There were only minor differences between the tissue results, and these ranges were therefore not drawn. between 1 and 3 days (Table II) , whereas the blood level had decreased during the same period (Figure 2) .
The uptake in DC filled with the cell medium only was not significantly different from the DC with the control cells (results not shown). Thus, the radioactivity in the control DC did mostly represent non-specific binding to the chamber components, and unbound antibodies in the fluid within the DC.
In vitro DC studies parallel to the mouse experiments With the artificial tumour system here presented, a comparison between in vitro and in vivo uptake could be performed. It is then possible during evaluation of the immunotargeting capacity of an antibody, to distinguish between pharmacokinetical and immunological factors. In vitro, the specific DC binding was somewhat higher with TP-1 than with H7; after 24 h there was a 1.4 times higher TP-1 uptake, increasing to 1.9 times at 72 h (Table III) . This minor difference between the two antibodies in vitro was in contrast to the results in the peritoneal cavity of mice, where a definitely larger difference was recorded; after 24 h there was a 8.6 times higher in vivo uptake of the TP-1 antibody than of H7, increasing to a ratio of 13.8 after 72 h (Table II) . Thus, when comparing the targeting potential of these two antibodies, it seems that most of the difference between their tumour cell uptake was caused by pharmacokinetical differences between Fab and F(ab')2, and only a minor part was due to different immunological binding characteristics.
Immunotargeting of tumour cells in domestic pigs
Like in the mouse experiments, the blood clearance of the two antibody preparations was recorded in the pigs before the targeting experiments were carried out (Figure 4) . Guided by these clearance curves, a 24 h period between MoAb injection and DC harvest was chosen for Fab, and a 72 h period for F(ab')2, e.g. the same time intervals that had given optimal targeting in the mice. The clearance rate of both antibodies was slower in the pigs than in mice. A higher blood level of antibodies in the pigs should enhance the tumour uptake in this species. With the intention to decrease the effect of this difference in clearance rate on the concentration of antibody available for the tumour cells during the study, the antibody doses given to the pigs were only increased 200 times relative to the doses injected on the mice, in spite of the fact that the body weight ratio between the two species was about 1,000.
The targeting experiments showed that the binding of both antibodies to the specific target did increase with increasing number of tumour cells (Figures 5 and 6 , Table IV ). Analogous to an in vitro assay, the degree of increase in the antibody uptake with increasing amount of tumour cells reflects partly the antibody avidity for the cells, and partly the number of specific binding sites on the cell surfaces relative to the amount of antibody available.
When comparing the results in mice and pigs, we found that the DC:blood ratios recorded in the pigs (Figures 5 and  6 ) were of the same order of magnitude as the ratios previously achieved in mice (Figure 3 ), whereas the DC uptake relative to injected dose was definitely lower in the pigs (Table IV) than in the mice (Table II) . The fraction of injected TP-1-F(ab')2 bound in the pig DC with 2 x i05 cells was 1/300 times the mouse DC uptake (2 x 105 cells). With H7-Fab the DC with half the cell number (i.e. 105 cells) did bind as much as 1/60 the uptake in the mice. Thus, the DC uptake values in pigs were definitely higher than expected from the mouse results. Several pig tissue specimens were explored for their radioactivity uptake, without being presented in Figure 5 and Figure 6 . There was an overall low radioactivity level in all these tissues. Different bone and cartilage specimens were carefully controlled for uptake of the anti-sarcoma antibody, and the level was low also in these tissues. 
Discussion
The main purpose of the preclinical in vivo evaluation of tumour specific MoAb is to measure the specific binding to the tumour cells, and to compare this with the antibody level in blood and the tissues. We here demonstrate that a diffusion chamber (DC) model can be utilised for this purpose in immunocompetent mice, and in xenogeneic species as well, domestic pigs being chosen in the present work.
The fact that immunocompetent animals of any species can be utilised is an important advantage of the model. As expected, we did find that the fraction of injected dose bound to the DC was much lower in large animals (pigs) than in small animals (mice). If we assume that the antibody distribution volume is the same fraction of the body weight in both species, then the distribution volume in pigs will be 1,000 times the distribution volume in mice. Then, according to the law of passive diffusion, the fraction of the injected dose diffusing into the DC in a pig should theoretically be about 1/1,000 times the value in a mouse, if the concentration of antibodies accessible to the DC was the same in the two species. However, the antibody uptake in the DC in pigs was higher than 1/1,000 the mouse results with the same DC, in spite of the fact that a five times lower weight-related dose had been administered to the pigs. We believe that the answer to this high DC uptake in the pigs may be that the blood clearance of the injected antibodies is slower in these animals than in the mice. This species difference in clearance rate was larger with the H7-Fab than with the TP-1-F(ab')2 antibody, and this may explain why the difference between measured and expected DC uptake in pigs was largest with the Fab antibody.
A very low percentage of the dose administered was expected to be bound to the relatively small amount of target cells in the DC. However, the fraction of the i.v. injected MoAb bound to 160 l target cell suspension, in DC placed intraperitoneally in mice, was comparable to the amount of antibody bound per gram xenograft tissue in nude mice. Assuming an average cell diameter of 20 tLm, 1 g of xenograft tissue contains about 1,000 times more cells than the DC. Thus, the antibody accessibility to the specific tumour cell antigen was definitely better in the DC cell suspension than in the nude mouse xenograft tissue. The explanation probably is that the antibody transport into solid tumours is hampered by anatomical and physiological barriers (Cobb, 1989; Jain, 1990 (Sands, 1990) .
With the DC model it was also possible to compare in vivo and in vitro MoAb binding to the same target. In vitro, the F(ab')2 uptake was somewhat higher than with the Fab fragment of the other MoAb, in spite of the fact that the avidity of the Fab was definitely higher. This means that the lower avidity of the F(ab')2 was compensated by the higher immunoreactive fraction and the higher number of binding sites on the target cells. In vivo, this difference between the specific uptake of the two antibodies was largely increased. The in vivo concentration of immunoreactive MoAb available for'reaction with the tumour cells is continuously reduced because the antibodies are catabolised, non-specifically bound in normal tissues, or, when small antibody fragments are used, excreted by the kidneys. This reduction in antibody concentration is presumably the main reason why a lower tumour uptake was recorded in vivo, especially in the case of the Fab antibody. In the experiments here presented the uptake with the Fab antibody was 40-50 times lower in mice than in vitro, whereas the in vivo tumour cell uptake with the F(ab')2 antibody was only 6-7 times lower than in vitro. It is thus difficult to achieve a high % injected dose in the target with a rapidly cleared antibody. On the other hand, a rapid blood clearance is preferred in tumour targeting studies because it reduces the background radiation.
Graft rejection is no problem in this model system. The immunocompetent cells of the host can not traverse the DC membrane wall. Theorectically though, the host humoral immune apparatus might be stimulated by immunogenic cell components that are shed from the tumour cells, and are small enough to leave the DC through the micropores. However, the period between i.p. implantation and harvest of the DC did not exceed 4 days, which is too short a time for an efficient primary humoral host versus graft response to develop. The cell viability and cell number in the DC in mice were followed in preliminary experiments not presented. Reliable registrations of cell growth and viability is first of all needed in immunotherapy studies. The total number of cells seemed to be constant during the observation period (3 days), and the fraction of dead cells (trypan blue dye exclusion test) increased from about 10% after I day in the DC to 20-40% after 3 days. However, the fraction of dead cells did not seem to influence the antibody uptake, at least not within the time intervals and the number of cells and antibody doses here used. Thus, when implanting DC with more than 50% trypan blue positive cells, we did not find uptake values significantly different from DC filled with cell suspensions with only 5% dead cells. We think that the reason for this is that the dead cells do not disintegrate to a considerable extent during the short observation period, but remain within the DC, and retain the ability to bind the antibodies. This may not be valid for other cell antigens.
Non-specific antibody binding in normal tissues is generally observed in immunotargeting. When the MoAb is given to species other than mice, a more reliable preclinical evaluation of the interaction with normal tissues is achieved. The probability for an immunological cross-reaction between murine MoAb and mouse tissues is low. However, when species other than mice are used, the MoAb are xenogeneic to the host animal, like in patients. The xenogeneic antibody transfer of murine MoAb to pigs in the present paper demonstrated a specific tumour cell targeting also in this species. This may predict that the MoAb preparations here utilised also have a good targeting potential in patients. In fact, promising results have now been achieved with TP-1 in several bone sarcoma patients (Bruland et al., manuscript in preparation) , and with H7 on ovarial cancer patients (Stigbrand et al., manuscript in preparation). 
